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ercutaneous Left Atrial Appendage Obliteration
idehiko Hara, MD,* Ray Matthews, MD,† Renu Virmani, MD,‡ David R. Holmes, MD,§
obert S. Schwartz, MD*
HE LEFT ATR IAL APPENDAGE (LAA) is responsible for about 90% of cardioembolic events
1) and LAA obliteration is often performed during cardiac surgery to minimize this risk. The LAA
bliteration is now feasible via a percutaneous approach. Patients are often poorly compliant with
nticoagulation (2), and anticoagulants are contraindicated in selected subsets of patients. A device or
ethod to reduce the risk of embolization from LAA thrombi, especially when associated anticoagu-
ation is not needed, would be a desired option in such patients. Studies comparing percutaneous LAA
bliteration with traditional anticoagulation are ongoing. The following ﬁgures offer some images of
he procedural details by standard angiographic and transesophageal echocardiographic (TEE) imaging.
he histopathologic consequence of the LAA obliteration is also shown.
orrespondence to: Robert S. Schwartz, MD, Minneapolis Heart Institute, 920 East 28th Street, Suite 620, Minneapolis, Minnesota 55407.
rom the *Minneapolis Heart Institute and Foundation, Minneapolis, Minnesota; †Good Samaritan Hospital, Los Angeles, California;
Selected Angiographic Images of the LAA Ablation Procedure
ft panel shows a catheter in the LAA. Injected contrast outlines the LAA and shows no ﬁlling defects (previously conﬁrmed by pre-proce-
The next panel shows contrast being injected through the device protruding out of the catheter tip. The remaining panel shows deploy-
subsequent withdrawal of the device delivery system.Figure 1.
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93Figure 2. Selected Echocardiographic Images of the LAA Ablation Procedure and the Histologic Process of Healing
The top left image of a representative TEE image shows a catheter properly
seated in the LAA. The LAA shows no ﬁlling defects. The next 2 images show
the device still attached to its delivery system and well seated in the ostium of
the LAA. These images also show the extent of deployment and the device’s
anatomic ﬁt. The next 3 images show intermediate steps of deployment and
withdrawal of the device delivery system. A few injected bubbles can be seen
as a thin jet (arrow) along the wall of the LAA and the adjacent wall of the
left atrium (LA). The next image, taken immediately after deployment, shows a
well-seated, fully deployed LAA occlusion device. The subsequent TEE images
are taken 45 days post-implantation as part of a protocol-mandated evaluation
of the Watchman device (Atritech Inc., Plymouth, Minnesota) from another
patient, an 88-year-old woman with chronic atrial ﬁbrillation and history of a
previous cerebrovascular accident. The device surface is a porous 160-m
polyester membrane mounted on a self-expanding Nitinol frame that ﬁlters
onstrated intimal coverage and endothelialization by 3 months. These images
show adequate device seating, and an echogenic shadow consistent with thin
tissue lining. Color Doppler shows a mild amount of ﬂow (which is seen as a
to-and-fro motion in Online Videos 1, 2, 3, 4). The histopathologic sections
have been obtained from this 88-year-old patient who died of renal failure,
unrelated to the device or cardiac causes, 4 months after implantation of the
device. The left histomicrograph shows healing of the atrial obliteration pro-
cess. The device is completely attached to the atrial wall, and there is a healed
ﬁbrous intimal tissue layer on the atrial surface. A partially organized thrombus
is present deep within the atrial appendage (25). This thrombus represents
static blood, and it is believed that this will become a ﬁbrous scar as it heals.
The right photomicrograph shows a close-up of the occluder device ﬁbers.
There is excellent healing of the atrial chamber contact surface. An organizing
thrombus is seen deep in this device and membrane layer (10).LAA blood entering and leaving the appendage. Pre-clinical studies have dem-
